- Home
- UCTT vs PHAT Comparison
UCTT vs PHAT Comparison
Compare UCTT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UCTT | PHAT |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 942.6M |
| IPO Year | 2004 | 2019 |
Fundamental Metrics
Financial Performance| Metric | UCTT | PHAT |
|---|---|---|
| Price | $43.72 | $13.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $32.50 | $17.33 |
| AVG Volume (30 Days) | 820.5K | ★ 1.4M |
| Earning Date | 02-23-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,110,600,000.00 | $147,190,000.00 |
| Revenue This Year | N/A | $220.82 |
| Revenue Next Year | $5.74 | $82.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.65 | ★ 460.30 |
| 52 Week Low | $16.66 | $2.21 |
| 52 Week High | $46.00 | $18.31 |
Technical Indicators
Market Signals| Indicator | UCTT | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 86.95 | 40.75 |
| Support Level | $31.17 | $13.79 |
| Resistance Level | $46.00 | $16.12 |
| Average True Range (ATR) | 1.99 | 0.95 |
| MACD | 1.60 | -0.33 |
| Stochastic Oscillator | 89.57 | 5.72 |
Price Performance
Historical ComparisonAbout UCTT Ultra Clean Holdings Inc.
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments Products and Services. Its principal markets are Americas, Asia Pacific and EMEA.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.